Madrigal Pharmaceuticals MDGL Q2 2026: Revenue Hits $364M, Up 71%
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Madrigal's MASH therapy Rezdiffra just crossed 50,000 patients as Q2 revenue surged 71% year-over-year, beating estimates by 3.3% on the back of accelerating physician adoption and a direct-to-consumer push that's turning a once-obscure liver disease into a scaled commercial opportunity.
Continue ReadingShow less
Rezdiffra, Madrigal's treatment for metabolic dysfunction-associated steatohepatitis (MASH), has now reached more than 50,000 patients, a milestone that is showing up clearly in the financials. Q2 2026 revenue came in at $364.3 million, clearing analyst estimates of $352.5 million by about 3.3% and marking a dramatic acceleration from the $14.6 million the company posted in Q2 2024. The sequential revenue trend tells the same story: from $311.3 million in Q1 2026 to $364.3 million in Q2 2026, the ramp shows no sign of flattening.
On the bottom line, Madrigal reported a loss of $1.99 per share against an estimated loss of $2.23, beating by roughly 11%. That narrowing loss, combined with surging top-line growth, reflects the commercial engine behind Rezdiffra gaining traction — both through accelerating physician adoption and a direct-to-consumer campaign that has raised awareness of a liver disease that was largely off the public radar before the drug's launch.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
The trajectory since Rezdiffra's commercial debut is striking: revenue has climbed from $62.2 million in Q3 2024 to $287.3 million in Q3 2025 to $364.3 million in this most recent quarter. Investors will be watching whether patient growth continues to outpace expectations and whether the DTC push can sustain the kind of physician-adoption momentum that has driven seven consecutive quarters of meaningful revenue gains.
Mentioned: MDGL